Antibody–drug conjugates headlined first-in-human development at ASCO, according to BioCentury’s analysis of 137 FIH studies highlighted at the meeting. The review found that ADCs accounted for about 20% of first-in-human trials, with a continued diversity of payloads, designs, and targets. The report also highlighted how China featured prominently for both translational programs and early-stage clinical research, while U.S. biopharmas maintained an edge in first-in-class clinical development. The takeaway for sponsors is continued investment in ADC platforms despite evolving payload and linker safety profiles.